Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice.
Marianna Fontana, Francesco Cappelli, Julian D Gillmore...
https://pubmed.ncbi.nlm.nih.gov/42533192/Actively Recruiting
Led by Bayer · Updated on 2026-10-08
2000
Participants Needed
17
Research Sites
N/A
Total Duration
Transthyretin Amyloid Cardiomyopathy ATTR-CM is a serious heart condition caused by the buildup of misfolded transthyretin protein in the heart muscle, leading to heart stiffness and progressive heart failure. There are two types a hereditary form and a wild-type form related to aging. Diagnosing ATTR-CM can be challenging because its symptoms resemble other heart diseases, but advances in medical imaging have improved early detection. Acoramidis is a new medication designed to stabilize the transthyretin protein and prevent harmful buildup. The ACO-REAL study is an observational research project aiming to collect real-world data on acoramidis use in patients with ATTR-CM. This study will observe adults diagnosed with either wild-type or variant ATTR-CM who are starting acoramidis treatment as part of their routine care in approximately 20 European countries. It includes patients new to treatment as well as those who have received other therapies. Researchers will document patient characteristics, how acoramidis is used in everyday clinical practice, and any side effects. The study does not introduce experimental treatments but follows patients receiving acoramidis according to normal medical standards. Participants will be followed for about 12 to 15 months after starting acoramidis. Researchers will collect data on heart function, functional capacity like walking ability, overall health, quality of life, and healthcare usage such as hospital visits. They will also monitor for adverse events during this period. This information aims to improve understanding of ATTR-CM and optimize patient care in real-world settings.
CONDITIONS
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
B
Bayer Clinical Trials Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Bayer
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 3 months
Participants are screened for eligibility to participate in the trial.
1 visit (signing informed consent and eligibility confirmation)
Duration - Approximately 12 to 15 months
Participants are observed while receiving acoramidis as part of their regular clinical care. Data on health status, heart function, treatment use, adverse events, and quality of life are collected.
Regular visits as per routine clinical practice
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Marianna Fontana, Francesco Cappelli, Julian D Gillmore...
https://pubmed.ncbi.nlm.nih.gov/42533192/Bayer
Lead Sponsor